India wants faster medical device approvals. Can it move quicker without compromising patient safety?

On an intensive care ward, a pulse oximeter quietly tracks falling oxygen levels. In an operating theatre, a cardiac stent restores blood flow that can mean the difference between life and death. In an orthopaedic clinic, a hip implant offers an elderly patient the chance to walk again. These devices rarely make headlines, yet every one of them reaches patients only after navigating a complex regulatory pathway designed to ensure that innovation does not come at the cost of safety.

India is now attempting to make that journey faster.

The Union Ministry of Health and Family Welfare has proposed amendments to the Medical Devices Rules, 2017 that would shorten statutory timelines for granting manufacturing licences for several categories of medical devices. The draft notification, published in the Official Gazette, seeks to reduce regulatory delays while retaining existing standards for quality, safety and performance.

At first glance, the proposal appears administrative. In reality, it sits at the intersection of industrial policy, healthcare access and regulatory science. It reflects India’s ambition to become a global medical device manufacturing hub while confronting an enduring question faced by every regulator: how quickly can approvals move without weakening oversight?

A regulatory system built on risk

Medical device regulation is fundamentally different from pharmaceutical regulation. Devices range from simple consumables to sophisticated implants and life-support technologies. Because the risks vary widely, most mature regulatory systems classify devices according to the level of risk they pose to patients.

India follows this internationally recognised approach under the Medical Devices Rules, 2017. Medical devices are categorised into four classes, from Class A, representing the lowest risk, to Class D, which includes the highest-risk products.

The proposed amendments do not alter this framework. Instead, they focus on how long manufacturers wait before receiving a manufacturing licence.

Under the draft notification:

• Manufacturing licence timelines for Class B devices would fall from 140 days to 115 days.
• Timelines for Class C and Class D devices would reduce from 105 days to 90 days.
• Every stage of the licensing process, including application scrutiny, audits by Notified Bodies, compliance verification and licence issuance, would receive clearly defined statutory timelines.

The Ministry of Health and Family Welfare says these changes are intended to improve regulatory efficiency, enhance ease of doing business and ensure that quality-assured medical devices become available to patients sooner.

The proposals are currently open for public consultation through the Central Drugs Standard Control Organisation (CDSCO).

Why the reforms matter beyond paperwork

Regulatory timelines influence far more than administrative efficiency.

For manufacturers, predictable approvals affect investment decisions, production schedules and the willingness to introduce new technologies. For hospitals, shorter licensing processes can translate into quicker access to domestically manufactured products. For patients, particularly those requiring devices such as cardiac stents, orthopaedic implants or monitoring equipment, regulatory delays may postpone availability of essential technologies.

The reforms also align with India’s broader policy direction.

The government has consistently sought to strengthen domestic manufacturing through initiatives such as Production Linked Incentive schemes, medical device parks and the National Medical Devices Policy 2023. Faster licensing complements these initiatives by reducing uncertainty for manufacturers without altering the underlying regulatory requirements.

Equally important is transparency.

By assigning timelines to every stage of review, the draft amendments attempt to make the licensing process more predictable for both regulators and industry. Defined milestones can improve accountability by identifying where delays occur instead of allowing applications to remain in prolonged administrative limbo.

In regulatory systems, predictability is often as valuable as speed.

Speed alone does not guarantee better regulation

The proposal, however, also highlights a familiar tension in healthcare regulation.

Medical devices are not ordinary consumer products. High-risk devices such as cardiac stents, hip implants and knee implants require detailed assessment of manufacturing systems, quality management processes and compliance with safety requirements before reaching patients.

Compressing timelines inevitably raises questions about whether regulatory agencies and Notified Bodies will have sufficient capacity to complete thorough reviews within shorter deadlines.

The draft amendments preserve existing quality, safety and performance requirements. Yet maintaining standards depends not only on legislation but also on implementation.

If inspectors, licensing authorities and Notified Bodies face workforce shortages or increasing application volumes, shorter statutory timelines could place pressure on review teams. The challenge is ensuring that efficiency comes from better processes rather than abbreviated assessments.

The distinction is critical. Faster decisions improve regulation only if scientific scrutiny remains unchanged.

Capacity may determine success

Much of the debate surrounding the draft amendments is therefore likely to centre not on the timelines themselves but on the systems required to support them.

Effective regulation depends on trained inspectors, competent Notified Bodies, digital application systems and coordinated functioning between Central and State Licensing Authorities.

Manufacturers also carry responsibility.

Incomplete applications, inadequate technical documentation or deficiencies in quality management systems have historically contributed to licensing delays. Defined review timelines will require applicants to submit complete and compliant dossiers from the outset.

The amendments therefore shift expectations to both regulators and industry.

Efficiency becomes a shared responsibility rather than a regulatory obligation alone.

Global principles favour efficient regulation, not rushed regulation

The proposals broadly reflect internationally accepted regulatory principles.

The International Medical Device Regulators Forum (IMDRF), of which India participates as an Affiliate Member through CDSCO, promotes risk-based regulation, transparent review processes and science-based decision making. IMDRF guidance encourages efficient and predictable regulatory systems but does not prescribe fixed approval timelines.

India’s amendments therefore represent a domestic implementation of internationally recognised regulatory principles rather than a departure from them.

The continued emphasis on risk classification, Quality Management Systems, conformity assessment and audits by Notified Bodies remains consistent with IMDRF guidance.

At the same time, IMDRF also emphasises that regulatory efficiency should never undermine scientific review. The success of India’s reforms will therefore depend less on the statutory numbers and more on whether the institutions responsible for implementing them have sufficient capacity to meet the new expectations.

The work does not end after approval

Every regulatory system must balance pre-market scrutiny with post-market surveillance.

Approving a device is only the beginning of its regulatory lifecycle. Monitoring adverse events, identifying manufacturing issues and responding to safety signals become increasingly important once devices enter routine clinical practice.

The proposed amendments focus specifically on manufacturing licence timelines. They do not address broader issues such as post-market vigilance, pathways for innovative devices, import regulation or local clinical evidence requirements.

That limitation does not diminish the value of the reforms. Rather, it highlights that regulatory modernisation is incremental. Faster licensing can improve efficiency, but sustained public confidence depends on robust oversight after products reach hospitals and patients.

A test of regulatory maturity

India’s medical device sector is entering a period of rapid transformation. Policymakers want to reduce import dependence, strengthen domestic manufacturing and position the country as a competitive global producer of medical technologies.

The proposed amendments to the Medical Devices Rules, 2017 reflect those ambitions.

They promise shorter licensing timelines, greater procedural transparency and improved regulatory predictability without formally lowering safety standards. If implemented alongside investments in regulatory capacity, digital infrastructure and effective post-market surveillance, they could strengthen both industry competitiveness and patient access.

The consultation process now underway provides an opportunity for manufacturers, clinicians, patient groups and regulatory experts to examine whether the compressed timelines remain compatible with rigorous scientific assessment.

Ultimately, this is not simply a debate about reducing 140 days to 115, or 105 days to 90.

It is a test of whether India’s regulatory system can demonstrate that efficiency and patient safety are complementary goals rather than competing priorities. If the answer is yes, the reforms could mark another step in India’s evolution towards a modern, internationally aligned medical device regulatory framework. If not, faster approvals may prove meaningful only on paper.